Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Rehabilitation Following Nasal Skin Cancer

NCT ID: NCT07257094

Last Updated: 2026-01-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

346 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-10

Study Completion Date

2027-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to validate a French version of the Nasal Reconstruction FACE-Q questionnaire for patients who have undergone nasal reconstruction or prosthetic rehabilitation after surgery for nasal skin cancer. The questionnaire evaluates appearance, quality of life, and possible side effects related to the reconstruction.

The investigators hypothesize that the validated French version will provide a reliable and standardized tool to assess patient satisfaction and health-related quality of life in this context.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Nasal skin cancers often require surgical excision that can result in significant tissue loss. Treatment may involve complex surgical reconstruction or, in some cases, prosthetic rehabilitation. These procedures may have major aesthetic, functional, and psychological consequences.

FACE-Q is an internationally recognized, patient-reported outcome instrument designed to assess satisfaction with appearance, health-related quality of life, and treatment-related adverse effects. However, FACE-Q was developed and validated in English and requires cultural and linguistic adaptation for reliable use in French-speaking populations.

This non-interventional, multicenter study aims to translate and validate the relevant FACE-Q Aesthetics scales in French for patients who have undergone nasal reconstruction or prosthetic rehabilitation after skin cancer. The selected domains address facial and nasal appearance, psychosocial well-being, social function, satisfaction with outcomes, and procedure-related adverse effects.

The expected outcome is to provide a standardized and validated French-language tool that reliably evaluates these patients' satisfaction and quality of life. Such a tool may be applied in clinical practice and future comparative research to improve patient care.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Operated patients

Patients with skin cancer in the nasal region who have undergone surgical reconstruction using a flap or rehabilitation using a prosthesis.

operated patients

Intervention Type OTHER

Response to the Nasal Reconstruction FACE-Q questionnaire, which includes the following scales :

* Appearence : Face overall, nose, nostrils, skin
* Health related quality of life (HRQOL) : Early life impact, psychological, social, outcome
* Adverse effects : on the nose, on the forehead, eyebrows and scalp
* Nasal Obstruction Symptom Evaluation (NOSE)
* Short-Form-36 (SF 36)

Control

Patients with no history of surgery or facial trauma

Control

Intervention Type OTHER

Response to the Nasal Reconstruction FACE-Q questionnaire, which includes the following scales :

* Appearence : Face overall, nose, nostrils, skin impact psychological, impact social,
* SF36

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

operated patients

Response to the Nasal Reconstruction FACE-Q questionnaire, which includes the following scales :

* Appearence : Face overall, nose, nostrils, skin
* Health related quality of life (HRQOL) : Early life impact, psychological, social, outcome
* Adverse effects : on the nose, on the forehead, eyebrows and scalp
* Nasal Obstruction Symptom Evaluation (NOSE)
* Short-Form-36 (SF 36)

Intervention Type OTHER

Control

Response to the Nasal Reconstruction FACE-Q questionnaire, which includes the following scales :

* Appearence : Face overall, nose, nostrils, skin impact psychological, impact social,
* SF36

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Patient who has undergone excision of a cutaneous, mucocutaneous, or vestibular nasal cancer with surgical reconstruction using a flap or prosthetic rehabilitation, performed more than 4 months ago, with stable results, and less than 3 years ago
* Patient informed of the study and not opposed to participation


* Age ≥ 65 years
* Subject informed and not opposed to participating in the study
* Subject who has never undergone facial trauma or surgery, and without major comorbidity, defined as follows:
* No heart failure (moderate or severe heart failure, history of heart attack within the last 6 months);
* No severe chronic respiratory disease (no stage III-IV COPD, no prolonged oxygen therapy);
* No uncontrolled diabetes or associated severe complications;
* No active immunosuppressive diseases or high-dose immunosuppressive treatment;
* No unstable or severe facial dermatological conditions;
* No comorbidities seriously affecting quality of life or respiratory function (at the investigator's discretion).

Exclusion Criteria

* Patient under anticoagulant or antiplatelet therapy Non-French-speaking patient
* Patient under legal protection (e.g., guardianship, legal safeguard) or with limited legal capacity
* Patient unlikely to cooperate with the study and/or poor anticipated compliance as judged by the investigator (including psychiatric disorders other than depressive disorder or cognitive impairment)
* Pregnant or breastfeeding woman

CONTROL


* Non-English speaking subject
* Subject under guardianship or legal protection, legally incompetent or with limited legal capacity
* Subject unlikely to cooperate in the study and/or anticipated low cooperation by the investigator (particularly those with psychiatric disorders other than depression or cognitive disorders)
* Pregnant or breastfeeding women
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hôpital NOVO

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Khaled AL TABAA, Doctor

Role: STUDY_DIRECTOR

Hôpital NOVO

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Caen

Caen, , France

Site Status NOT_YET_RECRUITING

Centre Antoine Lacassagne

Nice, , France

Site Status NOT_YET_RECRUITING

Institut Curie

Paris, , France

Site Status NOT_YET_RECRUITING

Hôpital Lariboisière (AP-HP)

Paris, , France

Site Status NOT_YET_RECRUITING

Hôpital Bichat (APHP)

Paris, , France

Site Status NOT_YET_RECRUITING

Hopital Novo

Pontoise, , France

Site Status RECRUITING

HNIA Toulon

Toulon, , France

Site Status NOT_YET_RECRUITING

CHU Toulouse

Toulouse, , France

Site Status NOT_YET_RECRUITING

Institut Gustave Roussy

Villejuif, , France

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Maxime HUMBERT, Dr

Role: primary

2 31 06 39 46

Gilles POISSONNET, Doctor

Role: primary

+33 4 92 03 14 38

Maria LESNIK, Doctor

Role: primary

01 44 32 45 35

Benjamin VERILLAUD, Pr

Role: primary

01 42 49 80 68

Caroline HALIMI LEVY, Doctor

Role: primary

+33 1 40 25 70 44

Khaled AL TABAA, Doctor

Role: primary

+33 1 30 75 40 40 ext. poste 71 51)

Jean-Baptiste MORVAN, Pr

Role: primary

+33 4 83 16 25 86

Guillaume DE BONNECAZE, Pr

Role: primary

05 67 77 17 88

Nadia BENMOUSSAREBIBO, Doctor

Role: primary

01 42 11 46 03

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHRD 1424

Identifier Type: OTHER

Identifier Source: secondary_id

2025-A02195-44

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CAncer, NUtrition and Taste 2
NCT05027490 COMPLETED NA